Helus Pharma Touts Positive Data for Depression Drug
Helus Pharma Inc. (NASDAQ:HELP) reported topline results from its pivotal Phase 3 APPROACH trial, showing its novel serotonergic agonist HLP003 rapidly and durably reduced symptoms in adults with major depressive disorder . Chief Executive Officer Michael Halstead said patients with persistent depression symptoms face a major unmet need for fast-acting, well-tolerated adjunctive therapies.…
We haven't written up this one. Benzinga has the full story — the link below goes straight to it.